铁螯合疗法改善铁过载患者慢性乙型肝炎：一例报告
Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload: A case report.
作者信息
Zou Dong-Mei, Rong Dong-Dong, Zhao Hong, Su Li, Sun Wan-Ling
机构信息
Department of Hematology Department of Radiology, Xuanwu Hospital, Capital Medical University, Beijing, P. R. China.
出版信息
Medicine (Baltimore). 2017 Dec;96(52):e9566. doi: 10.1097/MD.0000000000009566.
RATIONALE
This report describes seroconversion of hepatitis B surface antigen (HBsAg) in a patient with marked iron overload caused by chronic hepatitis B (CHB) after receiving iron chelation therapy and discusses the role of iron chelation therapy in CHB.
PATIENT CONCERNS
Increased serum ferritin level for 2 months.
DIAGNOSIS
Secondary iron overload and CHB.
INTERVENTION
To relieve iron load of the body, the patient underwent regular phlebotomy therapy and deferoxamine (DFO) therapy. During the therapy, serum ferritin and hepatitis B virus (HBV) were monitored and the iron concentration of the liver and heart were followed by T2* of magnetic resonance imaging (MRI) scan.
OUTCOMES
Serum ferritin gradually decreased. Approximately 1 year after the therapy, HBsAg turned persistently negative.
LESSONS
Iron chelation therapy may attenuate HBV infection.
原理
本报告描述了一名慢性乙型肝炎（CHB）导致明显铁过载的患者在接受铁螯合治疗后乙肝表面抗原（HBsAg）血清学转换情况，并讨论了铁螯合治疗在CHB中的作用。
患者情况
血清铁蛋白水平升高2个月。
诊断
继发性铁过载和CHB。
干预措施
为减轻身体铁负荷，患者接受了定期放血疗法和去铁胺（DFO）治疗。治疗期间，监测血清铁蛋白和乙型肝炎病毒（HBV），并通过磁共振成像（MRI）扫描的T2*追踪肝脏和心脏的铁浓度。
结果
血清铁蛋白逐渐下降。治疗约1年后，HBsAg持续转阴。
经验教训
铁螯合治疗可能减轻HBV感染。
Zotero 插件